Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621049 · ClinicalTrials.gov registry record · Phase 2
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
A Phase 2 study, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- Phase 2
- Development phase
- 112
- Enrollment target
NCT00621049 is a Phase 2 study that has completed, run by SCRI Development Innovations. The registered enrollment target is 112 participants.
The verdict
NCT00621049, a Phase 2 study, has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 112 participants
- Enrollment target
Study Summary
Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III NSCLC.
Interventions
- DRUG Docetaxel/Carboplatin/Bevacizumab/Erlotinib
- DRUG Docetaxel/Carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2007-12 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00621049
The ClinicalTrials.gov registry entry for NCT00621049 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 112 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel/Carboplatin/Bevacizumab/Erlotinib is the first listed.
NCT00621049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00621049 about?
NCT00621049 is a clinical study titled "Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC". Multicenter randomized phase II trial to examine the safety and efficacy of carboplatin, docetaxel, bevacizumab followed by maintenance bevacizumab and erlotinib in patients with completely resected stage IB, II, and select III NSCLC.
What is the current status of trial NCT00621049?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 112 participants. The study started on 2007-12. Estimated completion is 2014-02.
What interventions are being tested in trial NCT00621049?
The interventions under investigation include: Docetaxel/Carboplatin/Bevacizumab/Erlotinib (DRUG), Docetaxel/Carboplatin (DRUG).
Who is sponsoring clinical trial NCT00621049?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.